List of Studies ( Metabolite:BMP 18:0_20:4)
| Study_id | Analysis_id | Study_title | Source | Species | Disease | Institute | Analysis Type |
|---|---|---|---|---|---|---|---|
| ST004421 | AN007398 | Comparative lipidomics of iPSC-derived microglia protocols reveal lipid droplet and immune differences mediated by media composition | Human iPSC | Human | Alzheimers disease | VU Amsterdam | MS(Dir. Inf.) |
| ST004385 | AN007327 | Inducible deletion of DGAT1 and 2 from microglia exacerbates neurodegeneration and endolysosomal lipid accumulation in male PS19 mice | Brain | Mouse | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004230 | AN007042 | Effect of ATV:4D9 on Microglial Metabolism and FDG levels in mKate-TREM2/APP mouse model | Microglia | Mouse | Alzheimers disease | Denali Therapeutics | LC-MS |
| ST004223 | AN007028 | Sulfatide deficiency-induced astrogliosis and myelin lipid dyshomeostasis are independent of Trem2-mediated microglial activation | Brain | Mouse | Alzheimers disease | UT Health San Antonio | MS(Dir. Inf.) |
| ST004223 | AN007028 | Sulfatide deficiency-induced astrogliosis and myelin lipid dyshomeostasis are independent of Trem2-mediated microglial activation | Spinal cord | Mouse | Alzheimers disease | UT Health San Antonio | MS(Dir. Inf.) |
| ST004217 | AN007016 | Lipid Alterations in ASAH1-Deficient Cells: Insights into Ceramide Accumulation and Lysosomal Dysfunction | Cultured cells | Human | Metabolic disease | Harvard Medical School | LC-MS |
| ST004206 | AN006996 | Lipidomic Profiling of Sorted Microglia in GPR34-KO/APP-KI Mice Across 4, 8, 16, and 24 Months | Glial cells | Mouse | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004205 | AN006993 | Lipidomic/Metabolomic Characterization of GPR34 KO, WT, TREM2 KO, and GPR34/TREM2 dKO iPSC1-derived microglia | Glial cells | Human | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006909 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Metabolic disease | Denali Therapeutics | LC-MS |
| ST004163 | AN006909 | Targeted Lipid Profiling of HEK and iPSC derived iMG Cell Models with GBA1 Loss-of-Function | Cultured cells | Human | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006715 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Neurodegenerative disease | Denali Therapeutics | LC-MS |
| ST004059 | AN006715 | Targeted Lipid and Metabolite Profiling in Brains of ATP13A2 Knockout Mice | Brain | Mouse | Parkinsons disease | Denali Therapeutics | LC-MS |
| ST004057 | AN006706 | Microglial and Non-Microglial Regulation of Lipid Metabolism in Alzheimer's Revealed by Genetic and Pharmacological Depletion | Brain | Human | Alzheimers disease | UT Health San Antonio | MS(Dir. Inf.) |
| ST004057 | AN006706 | Microglial and Non-Microglial Regulation of Lipid Metabolism in Alzheimer's Revealed by Genetic and Pharmacological Depletion | Brain | Mouse | Alzheimers disease | UT Health San Antonio | MS(Dir. Inf.) |
| ST003664 | AN006021 | Tumour interstitial fluid-enriched phosphoethanolamine suppresses T cell function. | T-cells | Mouse | Cancer | University of Chicago | LC-MS |
